KMG Fiduciary Partners LLC Decreases Stake in Merck & Co., Inc. (NYSE:MRK)

KMG Fiduciary Partners LLC reduced its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 2.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 87,932 shares of the company’s stock after selling 1,895 shares during the quarter. Merck & Co., Inc. comprises about 1.5% of KMG Fiduciary Partners LLC’s portfolio, making the stock its 12th largest holding. KMG Fiduciary Partners LLC’s holdings in Merck & Co., Inc. were worth $8,017,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Santori & Peters Inc. raised its position in Merck & Co., Inc. by 8.5% during the 2nd quarter. Santori & Peters Inc. now owns 3,523 shares of the company’s stock worth $321,000 after buying an additional 275 shares during the last quarter. Franklin Street Advisors Inc. NC raised its position in Merck & Co., Inc. by 13.7% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 16,022 shares of the company’s stock worth $1,461,000 after buying an additional 1,925 shares during the last quarter. Monterey Private Wealth Inc. raised its position in Merck & Co., Inc. by 4.5% during the 2nd quarter. Monterey Private Wealth Inc. now owns 5,955 shares of the company’s stock worth $543,000 after buying an additional 256 shares during the last quarter. IMS Capital Management raised its position in Merck & Co., Inc. by 20.1% during the 2nd quarter. IMS Capital Management now owns 16,147 shares of the company’s stock worth $1,472,000 after buying an additional 2,704 shares during the last quarter. Finally, Private Advisor Group LLC raised its position in Merck & Co., Inc. by 7.2% during the 2nd quarter. Private Advisor Group LLC now owns 397,303 shares of the company’s stock worth $36,222,000 after buying an additional 26,654 shares during the last quarter. 73.33% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Up 3.5 %

Shares of MRK opened at $87.51 on Friday. Merck & Co., Inc. has a 52-week low of $71.50 and a 52-week high of $95.72. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The firm’s fifty day moving average is $88.83 and its two-hundred day moving average is $87.81. The stock has a market cap of $221.69 billion, a PE ratio of 13.40, a price-to-earnings-growth ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The company had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. During the same quarter in the previous year, the company posted $1.31 EPS. The firm’s quarterly revenue was up 28.0% on a year-over-year basis. Research analysts forecast that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.69 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 annualized dividend and a dividend yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is presently 42.27%.

Analysts Set New Price Targets

MRK has been the subject of a number of recent research reports. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research report on Friday, July 29th. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and lifted their target price for the company from $95.00 to $100.00 in a report on Wednesday, September 14th. Mizuho initiated coverage on shares of Merck & Co., Inc. in a report on Friday, June 24th. They set a “buy” rating and a $100.00 target price for the company. Cowen lifted their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. Finally, Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and lifted their price target for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $98.28.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.